Lilly Nears $1B+ Deal to Acquire Ventyx Biosciences, Bolstering Oral Anti-inflammatory Pipeline

Jan 07, 2026 10:33 CST Updated 10:33

Ventyx

Small Molecule Therapy Developer

Eli Lilly

Global Pharmaceutical R&D and Production Company

Note:This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy.This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

PharmaCircleMonitoring shows:Recently, Eli Lilly and Company's acquisition of Ventyx Biosciences may be about to be announced. (Based on the post-market increase, a temporary price hike for the acquisition might be necessary. However, for Eli Lilly, this is just a drop in the bucket.)

The target is shown in the figure and will also be described in the text below.

This acquisition will help Eli Lilly further expand its business in the field of inflammatory diseases, going beyond its existing diabetes and obesity drugs, including Trulicity and Mounjaro.

Ventyx's NLRP3 inhibitor targets the NLRP3 inflammasome, a key component of the immune system associated with various chronic diseases. The company's VTX3232, an NLRP3 inhibitor capable of penetrating the central nervous system, has shown promising results in Phase 2a clinical trials for Parkinson's disease.

On Tuesday, Eli Lilly also announced another collaboration with Nimbus Therapeutics to jointly develop oral therapies for obesity.

2. Core Transaction Information

Project	Details
Both Parties to the Transaction	Acquirer: Eli Lilly and Company Target: Ventyx Biosciences, Inc.
Transaction Amount	Over $1 Billion ($1 billion+)
Negotiation Stage	Advanced talks, possible announcement imminent
Ventyx Core Assets	1. NLRP3 Inhibitors: VTX2735 (Recurrent Pericarditis, Phase II), VTX3232 (Parkinson's Disease, Positive Phase IIa Results) 2. TYK2 Inhibitor: VTX002 (Psoriasis/Inflammatory Bowel Disease, Phase II) 3. Other Oral Small Molecule Anti-inflammatory Drugs
Eli Lilly Strategic Intent	1. Expand the immunology/inflammatory disease pipeline2. Supplement the layout in the neurodegenerative disease field3. Strengthen the R&D capability of oral small molecule drugs
Market Response	Ventyx Shares Soar Over 60% in After-Hours Trading, Closing Up 28.5%
Ventyx Headquarters	San Diego, California, USA

References:

PharmaCircle Data;

MoEntropy Pharma pharma.bcpmdata.com (formerly Pharma Data Cloud); etc.

StreetInsider；

https://www.morningstar.com/news/dow-jones/202601066718/ventyx-biosciences-gains-on-report-of-possible-1-billion-eli-lilly-deal；

Etc.